 |
|
 Notice |
|
|
42.03 €
|
|
Ethics and the pharmaceutical industry: business, government, professional, and advocacy perspectives
Auteur(s) : SANTORO Michael A., GORRIE Thomas M.
Date de parution: 12-2005
Langue : ANGLAIS
480p. 23.5x16.3 Hardback
Etat : Disponible chez l'éditeur (délai de livraison : 10 jours)
| Résumé | | Charting a sustainable path for the 21st century pharmaceutical industry Michael A. Santoro, Part I. Profits, Patients’ Rights, and Scientific Progress: The Ethics of Clinical Research Conducted in Private Enterprises: 1. Drug research: between ethical demands and economic constraints Jurgen Drews, 2. Emerging international norms for clinical testing: good clinical trial practice Juhana E. Idanpaan-Heikkila and Sev S. Fluss, 3. The regulatory and ethical challenges of pediatric research M. Dianne Murphy and Sara F. Goldkind, 4. Including children in research: participation or exploitation? Robert M. Nelson, 5. Racial and ethnic inclusiveness in clinical trials Valentine J. Burroughs, 6. The rights of patients to participate in clinical trials Glenna Crooks, 7. How should government regulate stem-cell research? perspectives of a scientist-legislator The Hon. Rush Holt, Part II. Marketing and the Efficient Utilization of Healthcare Resources: Ethical and Public Policy Challenges: 8. Ethics and prescribing: the clinician’s perspective Charles L. Bardes, 9. Direct-to-consumer advertising of prescription drugs: a policy dilemma Meredith B. Rosenthal and Julie M. Donohue, 10. Regulation of prescription drug promotion Thomas Abrams, 11. Off-label communications in marketing prescription drugs Scott D. Danzis, 12. The need for better health information: advancing the informed patient in Europe Don E. Detmer, Peter Singleton and Scott C. Ratzan, 13. Who should get access to which drugs? An ethical template for pharmacy benefits Norman Daniels, James E. Sabin and J. Russell Teagarden, 14. The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals Joel Hay, Part III. Patents, Pricing, and Equal Access: 15. Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities Patricia H. Werhane and Michael Gorman, 16. A future agenda for government-industry relations William Weldon, 17. AIDS activism and the pharmaceutical industry Martin Delaney, 18. The campaign against innovation Sidney Taurel, 19. Third world perspectives on global pharmaceutical access James Thuo Gathii, 20. The promise of vaccines and the influenza shortage of 2004: public and private partnerships Gary R. Noble, Part IV. Charting a Sustainable Path for the 21st Century: 21. Evolving approaches to healthcare challenges Thomas M. Gorrie, 22. Property rights in crisis: managers and rescue Nien-he Hsieh, 23. Blurring the lines: public and private partnerships addressing global health William Foege, 24. Renegotiating the grand bargain: balancing prices, profits, people, and principles Greg Koski. |
| Sommaire | | Charting a sustainable path for the 21st century pharmaceutical industry Michael A. Santoro, Part I. Profits, Patients? Rights, and Scientific Progress: The Ethics of Clinical Research Conducted in Private Enterprises: 1. Drug research: between ethical demands and economic constraints Jurgen Drews, 2. Emerging international norms for clinical testing: good clinical trial practice Juhana E. Idanpaan-Heikkila and Sev S. Fluss, 3. The regulatory and ethical challenges of pediatric research M. Dianne Murphy and Sara F. Goldkind, 4. Including children in research: participation or exploitation? Robert M. Nelson, 5. Racial and ethnic inclusiveness in clinical trials Valentine J. Burroughs, 6. The rights of patients to participate in clinical trials Glenna Crooks, 7. How should government regulate stem-cell research? perspectives of a scientist-legislator The Hon. Rush Holt, Part II. Marketing and the Efficient Utilization of Healthcare Resources: Ethical and Public Policy Challenges: 8. Ethics and prescribing: the clinician?s perspective Charles L. Bardes, 9. Direct-to-consumer advertising of prescription drugs: a policy dilemma Meredith B. Rosenthal and Julie M. Donohue, 10. Regulation of prescription drug promotion Thomas Abrams, 11. Off-label communications in marketing prescription drugs Scott D. Danzis, 12. The need for better health information: advancing the informed patient in Europe Don E. Detmer, Peter Singleton and Scott C. Ratzan, 13. Who should get access to which drugs? An ethical template for pharmacy benefits Norman Daniels, James E. Sabin and J. Russell Teagarden, 14. The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals Joel Hay, Part III. Patents, Pricing, and Equal Access: 15. Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities Patricia H. Werhane and Michael Gorman, 16. A future agenda for government-industry relations William Weldon, 17. AIDS activism and the pharmaceutical industry Martin Delaney, 18. The campaign against innovation Sidney Taurel, 19. Third world perspectives on global pharmaceutical access James Thuo Gathii, 20. The promise of vaccines and the influenza shortage of 2004: public and private partnerships Gary R. Noble, Part IV. Charting a Sustainable Path for the 21st Century: 21. Evolving approaches to healthcare challenges Thomas M. Gorrie, 22. Property rights in crisis: managers and rescue Nien-he Hsieh, 23. Blurring the lines: public and private partnerships addressing global health William Foege, 24. Renegotiating the grand bargain: balancing prices, profits, people, and principles Greg Koski. |
Thèmes :
- Economie et gestion des entreprises / Organisation de l'entreprise / Ouvrages généraux
|
| |
|
|
|
|
|
|
